| Primary |
| Multiple Sclerosis |
90.1% |
| Drug Use For Unknown Indication |
2.4% |
| Product Used For Unknown Indication |
2.3% |
| Relapsing-remitting Multiple Sclerosis |
1.4% |
| Hypertension |
0.6% |
| Premedication |
0.6% |
| Depression |
0.5% |
| Prophylaxis |
0.3% |
| Pain |
0.3% |
| Drug Exposure During Pregnancy |
0.2% |
| Diabetes Mellitus |
0.2% |
| Muscle Spasms |
0.2% |
| Anxiety |
0.2% |
| Convulsion |
0.1% |
| Asthma |
0.1% |
| Gait Disturbance |
0.1% |
| Muscle Spasticity |
0.1% |
| Fatigue |
0.1% |
| Blood Cholesterol Increased |
0.1% |
| Hypothyroidism |
0.1% |
|
| Multiple Sclerosis Relapse |
9.7% |
| Death |
9.5% |
| Pneumonia |
6.0% |
| Influenza Like Illness |
5.6% |
| Urinary Tract Infection |
5.5% |
| Memory Impairment |
5.3% |
| Multiple Sclerosis |
5.3% |
| Myocardial Infarction |
5.2% |
| Tremor |
5.1% |
| Vomiting |
4.6% |
| Pain |
4.5% |
| Pyrexia |
4.4% |
| Stress |
4.1% |
| Fall |
3.9% |
| Pain In Extremity |
3.9% |
| Weight Decreased |
3.8% |
| Injection Site Haemorrhage |
3.7% |
| Visual Impairment |
3.3% |
| Breast Cancer |
3.3% |
| Gait Disturbance |
3.2% |
|
| Secondary |
| Multiple Sclerosis |
90.8% |
| Drug Use For Unknown Indication |
2.2% |
| Product Used For Unknown Indication |
1.6% |
| Relapsing-remitting Multiple Sclerosis |
1.1% |
| Premedication |
0.8% |
| Depression |
0.6% |
| Hypertension |
0.5% |
| Muscle Spasms |
0.3% |
| Pain |
0.3% |
| Gait Disturbance |
0.2% |
| Anxiety |
0.2% |
| Prophylaxis |
0.2% |
| Diabetes Mellitus |
0.2% |
| Muscle Spasticity |
0.2% |
| Convulsion |
0.2% |
| Fatigue |
0.1% |
| Back Pain |
0.1% |
| Asthma |
0.1% |
| Trigeminal Neuralgia |
0.1% |
| Blood Cholesterol Increased |
0.1% |
|
| Multiple Sclerosis Relapse |
10.6% |
| Influenza Like Illness |
6.4% |
| Urinary Tract Infection |
6.3% |
| Vomiting |
5.8% |
| Tremor |
5.5% |
| Pneumonia |
5.4% |
| Memory Impairment |
5.3% |
| Pain |
5.0% |
| Weight Decreased |
4.9% |
| Myocardial Infarction |
4.7% |
| Pain In Extremity |
4.6% |
| Underdose |
4.5% |
| Multiple Sclerosis |
4.3% |
| Pyrexia |
4.3% |
| Visual Impairment |
4.2% |
| Stress |
4.0% |
| Injection Site Haemorrhage |
3.8% |
| Death |
3.7% |
| Injection Site Pain |
3.5% |
| Fall |
3.4% |
|
| Concomitant |
| Multiple Sclerosis |
96.3% |
| Product Used For Unknown Indication |
1.2% |
| Relapsing-remitting Multiple Sclerosis |
0.4% |
| Drug Use For Unknown Indication |
0.3% |
| Premedication |
0.3% |
| Pain |
0.2% |
| Gait Disturbance |
0.2% |
| Depression |
0.2% |
| Hypertension |
0.1% |
| Muscle Spasms |
0.1% |
| Anxiety |
0.1% |
| Fatigue |
0.1% |
| Headache |
0.1% |
| Gastrooesophageal Reflux Disease |
0.1% |
| Insomnia |
0.1% |
| Muscle Spasticity |
0.1% |
| Migraine |
0.0% |
| Diabetes Mellitus |
0.0% |
| Sleep Disorder |
0.0% |
| Pain In Extremity |
0.0% |
|
| Multiple Sclerosis Relapse |
13.3% |
| Fatigue |
11.7% |
| Urinary Tract Infection |
8.2% |
| Malaise |
6.9% |
| Headache |
6.1% |
| Multiple Sclerosis |
5.8% |
| Drug Ineffective |
5.0% |
| Memory Impairment |
4.9% |
| Gait Disturbance |
4.8% |
| Nasopharyngitis |
4.5% |
| Pain |
3.7% |
| Pain In Extremity |
3.6% |
| Vomiting |
3.0% |
| Asthenia |
3.0% |
| Stress |
2.8% |
| Muscular Weakness |
2.8% |
| Sinusitis |
2.5% |
| Nausea |
2.5% |
| Visual Impairment |
2.5% |
| Poor Venous Access |
2.4% |
|
| Interacting |
| Bipolar Disorder |
40.0% |
| Multiple Sclerosis |
40.0% |
| Decreased Appetite |
20.0% |
|
| Drug Interaction |
50.0% |
| Mania |
50.0% |
|
